Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.

• Príomhchruthaitheoirí: Eltahir A G Khalil (Údar), Teklu Weldegebreal (Údar), Brima M Younis (Údar), Raymond Omollo (Údar), Ahmed M Musa (Údar), Workagegnehu Hailu (Údar), Abuzaid A Abuzaid (Údar), Thomas P C Dorlo (Údar), Zewdu Hurissa (Údar), Sisay Yifru (Údar), William Haleke (Údar), Peter G Smith (Údar), Sally Ellis (Údar), Manica Balasegaram (Údar), Ahmed M EL-Hassan (Údar), Gerard J Schoone (Údar), Monique Wasunna (Údar), Robert Kimutai (Údar), Tansy Edwards (Údar), Asrat Hailu (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Public Library of Science (PLoS), 2014-01-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Anti-leishmanial drug regimens that include a single dose AmBisome could be suitable for eastern African patients with symptomatic visceral leishmaniasis (VL) but the appropriate single dose is unknown.A multi-centre, open-label, non-inferiority, randomized controlled trial with an adaptive design,...